Influence of partial liquid ventilation on bacterial growth and alveolar expansion in newborn rabbits with group B-streptococcal pneumonia.
Partial liquid ventilation (PLV) with perfluorocarbons has been considered as an alternative therapy for severe inflammatory lung disease. The present study was performed to test whether PLV influences bacterial growth and lung histology in a rabbit model of congenital pneumonia caused by group B streptococci. Near-term newborn rabbits were tracheotomized, inoculated via the airways with group B streptococci, and subsequently ventilated for 5 h with either PLV or conventional ventilation. At 30 min after group B streptococci administration, animals in the PLV group (n = 16) received 30 mL/kg body weight of perfluorocarbon (PF 5080) via the tracheal tube. Evaporative losses were substituted with 20 mL/kg perfluorocarbon at hourly intervals. Identical volumes of air were injected in control animals at the same times (n = 15). The number of colony-forming units in left lung homogenate, evaluated at the end of the experiments, tended to be lower in PLV-treated animals than in controls (6.8 x 109 versus 6.4 x 1010 colony-forming units/g body weight; p = 0.06). Comparison of these numbers with the colony-forming units injected at the beginning of the experiments revealed a reduction in bacterial number in the PLV group and proliferation in the controls (-2.2 x 108 versus +5.6 x 1010 colony-forming units/g body weight; p < 0.05). Histologic examination demonstrated less inflammation and more homogeneous lung expansion in PLV-treated animals. Two animals in the PLV group had focal interstitial emphysema. Our results suggest that PLV with PF 5080 reduces bacterial proliferation in experimental group B streptococcal pneumonia.
Rudiger
Mario
M
Department of Surgical Sciences, Karolinska Hospital, Huddinge University Hospital, Stockholm, Sweden. Germany.
Some
Margareta
M
Jarstrand
Connie
C
Calkovska
Andrea
A
Linderholm
Bim
B
Robertson
Bengt
B
Herting
Egbert
E
D000818:Animals; D004195:Disease Models, Animal; D005260:Female; D005466:Fluorocarbons / Q000494:pharmacology; D006098:Granulocytes / Q000276:immunology; D021061:Liquid Ventilation; D018410:Pneumonia, Bacterial / Q000276:immunology / Q000503:physiopathology* / Q000628:therapy; D011247:Pregnancy; D011650:Pulmonary Alveoli / Q000382:microbiology* / Q000473:pathology / Q000503:physiopathology; D011817:Rabbits; D013290:Streptococcal Infections / Q000276:immunology / Q000503:physiopathology* / Q000628:therapy; D013292:Streptococcus agalactiae / Q000187:drug effects / Q000254:growth & development*
D005466:Fluorocarbons